The Orange Book is a critical tool for drugmakers because they can sue a generic developer who applies for approval of a product with a listed patent, blocking the entry of a copycat medicine for 30 ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
FTC targets 300 Big Pharma 'junk patents,' sends warning letters to top drugmakers The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book ...